Steven Leonard Chapman Sells 9,563 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 9,563 shares of the business’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $1,323,614.83. Following the sale, the chief executive officer now directly owns 212,541 shares in the company, valued at approximately $29,417,799.81. This represents a 4.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, March 17th, Steven Leonard Chapman sold 6,702 shares of Natera stock. The stock was sold at an average price of $146.03, for a total transaction of $978,693.06.
• On Wednesday, March 5th, Steven Leonard Chapman sold 87,272 shares of Natera stock. The shares were sold at an average price of $143.40, for a total value of $12,514,804.80.
• On Wednesday, January 29th, Steven Leonard Chapman sold 13,685 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $2,269,930.95.
• On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41.

Natera Stock Performance

NTRA opened at $140.65 on Wednesday. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The firm has a market capitalization of $19.01 billion, a PE ratio of -79.91 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm’s 50-day moving average price is $158.72 and its 200 day moving average price is $151.35.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on NTRA shares. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a report on Wednesday, March 19th. Sanford C. Bernstein lifted their target price on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, January 10th. Robert W. Baird increased their price target on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Royal Bank of Canada started coverage on shares of Natera in a report on Thursday, March 13th. They issued an “outperform” rating and a $251.00 price objective for the company. Finally, The Goldman Sachs Group raised their target price on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $178.12.

Institutional Trading of Natera

Large investors have recently added to or reduced their stakes in the stock. LRI Investments LLC acquired a new position in shares of Natera during the 4th quarter valued at about $29,000. Blue Trust Inc. raised its stake in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc boosted its holdings in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after buying an additional 261 shares during the period. Finally, Principal Securities Inc. increased its holdings in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after buying an additional 59 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.